注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
ProQR Therapeutics NV是一家位於荷蘭的臨床前生物製藥公司。該公司從事發現和開發基於核糖核酸(RNA)的治療嚴重遺傳疾病的療法。它設計其治療候選物以專門針對和修復有缺陷的信使RNA或信使核糖核酸(mRNA),該信使核糖核酸(mRNA)從突變基因轉錄而來,以恢復正常或野生型蛋白質的表達和功能。其候選產品包括QR-010,一種用於治療囊性纖維化(CF)的基於RNA的寡核苷酸,QR-110,一種用於治療Leber先天性黑蒙(LCA)的寡核苷酸。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Donald S. Fong | - | 2020 | Member of Scientific Advisory Board |
Bart Filius | 51 | 2019 | Independent Supervisory Board Member |
James S. Shannon | 65 | 2016 | Independent Member of Supervisory Board & Chairman of Scientific Advisory Board |
Domenico Valerio | 66 | 2014 | Founder & Independent Chairman of Supervisory Board |
Theresa Marie Heggie | 64 | 2021 | Supervisory Board Member |
Alison F. Lawton | 63 | 2014 | Independent Member of Supervisory Board |
Peter A. Beal | - | 2018 | Member Scientific Advisory Board |
Phillip D. Zamore | - | 2017 | Member of Scientific Advisory Board |
Yi-Tao Yu | - | 2018 | Member of Scientific Advisory Board |
Martin A. Maier | - | 2020 | Member of Scientific Advisory Board |
Begona Carreno | 53 | 2023 | Supervisory Board Member |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核